Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Complete title: Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients with Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 OR L858R +/- T790M) Non-Small Cell Lung Cancer

Research Study Number 20150645
Principal Investigator Renato Martins, MD, MPH
Phase I/II

Research Study Description

Phase 1: The Phase 1 study is an open label, multi center, multiple dose, non randomized, safety, pharmacokinetic, and pharmacodynamics dose escalation study of PF 06747775 as a single agent in patients with advanced EGFRm NSCLC (del19 or L858R, +/ -T790M).

Phase 2: an open label, multi-center, single arm study of PF-06747775 for the assessment of anti-tumor activity in patients with advanced EGFRm (del19 or L858R) advanced NSCLC with T790M (del 19 and T790M or L858R and T790M) and further pharmacokinetic characterization.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20150645
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Lung Cancer; Solid Tumors; Carcinoma, Bronchogenic

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials